Vimarsana
Biggest News Aggregation in the World

Page 2 - Michael Platten News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Platten. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Platten Today - Breaking & Trending Today

New form of cellular immunotherapy shows promise against brain tumors in mice - Vimarsana News

New form of cellular immunotherapy shows promise against brain tumors in mice

Scientists from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) successfully tested a new form of cellular immunotherapy against brain tumors in mice for the first time.

Peptide vaccine targets H3K27M mutation in midline gliomas, shows promise in early trials - Vimarsana News

Peptide vaccine targets H3K27M mutation in midline gliomas, shows promise in early trials

Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are carrying cancer-typical alterations.

Hocus focus: Local business owner creates theater for magic shows - Vimarsana News

Hocus focus: Local business owner creates theater for magic shows

Diamond Jim Tyler will join Michael Platten and daughter Sophia Platten for three weekend shows at Magic Attic Theater.

Ardigen and DKFZ research groups are entering into a collaboration to evaluate the safety of TCR-based therapies (TCR-Ts) - Vimarsana News

Ardigen and DKFZ research groups are entering into a collaboration to evaluate the safety of TCR-based therapies (TCR-Ts)

Ardigen and DKFZ research groups are entering into a collaboration to evaluate the safety of TCR-based therapies (TCR-Ts)

Ardigen and DKFZ research groups are entering into a collaboration to evaluate the safety of TCR-based therapies (TCR-Ts) - Vimarsana News

Ardigen and DKFZ research groups are entering into a collaboration to evaluate the safety of TCR-based therapies (TCR-Ts)

Ardigen and DKFZ research groups are entering into a collaboration to evaluate the safety of TCR-based therapies (TCR-Ts)